By Zachery Onyango | Project Leader
Dear Donor,
The current Ebola emergency is also generating important scientific evidence that could strengthen future outbreak preparedness.
Bundibugyo virus is different from the Ebola virus for which the licensed Ervebo vaccine is specifically indicated. WHO states that there is currently no licensed vaccine specifically for Bundibugyo virus disease.
In August, 70,000 Ervebo doses were allocated to the DRC: 50,000 for frontline and health workers and 20,000 for a Phase 3 clinical trial examining its potential impact against Bundibugyo virus.
WHO emphasizes that protection against Bundibugyo virus in humans has not yet been established.
Development Alert continues supporting community awareness around accurate health information and responsible engagement with public health interventions.
Your support helps communities remain informed as science and the response continue to evolve.
Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.
Support this important cause by creating a personalized fundraising page.
Start a Fundraiser
